The critical role of Atpif1 in Her2-targeted CAR-T cell therapy for solid tumor via modulation of metabolism and mtDNA-STING signal pathway
Our findings highlight the dual role of ATPIF1 in CAR-T cell therapy: while its overexpression boosts metabolic activity <i>in vitro</i>, its knockdown enhances adaptability to the hypoxic tumor microenvironment <i>in vivo</i>, indicating the paradox for modulating the antitumor activities of CAR-T cells via the metabolic remodeling for the treatment of solid tumor. These insights suggest that targeting ATPIF1 or the STING pathway could optimize CAR-T cell efficacy in solid tumors, bridging the gap between <i>in vitro</i> performance and <i>in vivo</i> outcomes.
Authors
- Xingya Zhang
- Z. Q. Chen
- Biliang Hu (ORCID: https://orcid.org/0009-0000-0874-5179)
- Xue Gong (ORCID: https://orcid.org/0000-0001-5201-3661)
- Genshen Zhong
- Minna Wu
- Xinyu Luo
- Shuyin Zheng
- Qi Wang
- Biao Liu
Institutions
- Unitika (Japan) (JP)
- Changsha University (CN)
- Henan University of Technology (CN)
- Changsha University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-03-02
- DOI
- https://doi.org/10.3389/fimmu.2026.1733753
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Education Department of Hunan Province
- National Natural Science Foundation of China